© 2021 MJH Life Sciences and Opthalmology Times Europe. All rights reserved.
© 2021 MJH Life Sciences™ and Opthalmology Times Europe. All rights reserved.
September 12, 2021
Health systems are challenged to provide appropriate care for the ever-increasing number of patients with diabetes and its complications, such as diabetic retinopathy and diabetic macular oedema.
September 11, 2021
During a presentation at the EURETINA 2021 Virtual Congress, Dr Daniel Jones discussed GA and emphasized the need for additional study to gain a better understanding of the burden experienced by patients.
In a presentation at the EURETINA 2021 Virtual Congress, Dr Cristina Cristian noted that an injection of brolucizumab treatment in patients with neovascular age-related macular degeneration led to a median improvement in visual acuity (VA) of 10.5 letters and the drug was well-tolerated.
Dr Ramin Tadayoni discusses the myopia panel at the EURETINA 2021 virtual meeting.
Dr Grazia Pertile discusses the highlights of her presentations on the management of retinal folds after retinal detachment and the role of the anterior vitreous as a cause of recurrent retinal detachment.
Prof Carel B. Hoyng discusses his presenation regarding macula dystrophies, including Stargardt disease, Best disease, X-linked retinoschisis, and the peripherin-2 (PRPH2) gene.
September 10, 2021
During a presentation at the EURETINA 2021 Virtual Congress, Dr Anat Loewenstein discussed how artificial intelligence can optimize optical coherence tomography.
During a presentation at the EURETINA 2021 Virtual Congress, Dr José-Alain Sahel explains that optogenetics involves the use of artificial photoreceptors from specific retinal cells to restore vision by transferring a gene that encodes for a light-sensitive protein that causes neuronal cells to respond to light stimulation.
Dr Javier Zarranz-Ventura discusses the key highlights from his presentation on a clinical investigation of suitable naïve versus pretreated DMO patients, and what it means for future research.
September 09, 2021
Dr Jennifer Sun explores the question of whether ophthalmologists should be using anti-VEGF agents to treat patients with nonproliferative diabetic retinopathy (NPDR).